AHSCT and the long arc of disability in aggressive multiple sclerosis
Progression independent of relapse activity, or PIRA, has become one of the most frustrating patterns in multiple sclerosis care because it can erode function even when overt relapses are quiet. In aggressive relapsing-remitting MS, the central question is no longer only whether a treatment suppresses inflammatory attacks. It is whether the therapy can also alter the slower biological processes that drive disability accumulation over years.
A comparative matched study from Florence brings that question into sharper focus. Patients who underwent autologous haematopoietic stem cell transplantation with BEAM/ATG conditioning were compared with patients who started natalizumab, with a second control framework extending natalizumab follow-up into subsequent disease-modifying therapy exposure after discontinuation. The follow-up was long, with a median duration of 106 months, giving the cohort enough time for divergence in progression biology to emerge if the treatment effect was real.
Why peripheral relapse control may not be enough
The rationale behind the analysis is biologically direct. Many standard disease-modifying therapies mainly target adaptive immunity in the periphery, which can sharply reduce relapses yet leave behind the compartmentalized central nervous system inflammation and neurodegenerative signaling that sustain PIRA. BEAM/ATG conditioning used in AHSCT introduces chemotherapy that is bioavailable within the CNS, making it plausible that the approach could affect immune activity beyond the bloodstream and lymphoid tissue.
That mechanism matters in aggressive MS, where relapse suppression and long-term progression do not always travel together. A treatment can look excellent in the short run and still fail to prevent the gradual loss of neurologic reserve that eventually determines disability. The study was designed around that gap.
Matched cohorts and long follow-up
This retrospective propensity-score matched study included 30 relapsing-remitting MS patients treated with AHSCT and 30 controls who began natalizumab at the same center between 2007 and 2018. The design cannot eliminate every source of confounding, but propensity matching is a meaningful attempt to compare patients with broadly similar baseline characteristics. The endpoint structure also separates two clinically important windows: the natalizumab treatment epoch, during which controls were censored when they stopped natalizumab, and the whole follow-up, which included later treatment switches and therefore reflects the longer therapeutic course that real patients actually experience.
A practical detail stood out immediately: 29 of 30 natalizumab-treated patients discontinued the drug and moved on to alternative disease-modifying therapy. That pattern makes the longer-term comparison especially relevant, because many MS patients do not remain on the first advanced therapy indefinitely.
PIRA divergence appears only over time
During the natalizumab treatment epoch, the cumulative proportion of patients with PIRA did not differ between groups. The p value was 0.990, a signal of no detectable separation while natalizumab was actively controlling inflammation.
The picture changed over the full follow-up. AHSCT-treated patients had a lower cumulative proportion with PIRA than the natalizumab-to-other-DMT sequence group, reaching 10% versus 21% at year 5 and 10% versus 49% at year 10, with p=0.020. Those curves suggest that the advantage of transplantation is not immediately visible in the narrow window of relapse suppression alone. It emerges when progression biology is allowed to unfold across many years.
The secondary outcomes moved in the same direction. AHSCT outperformed natalizumab on relapses and on NEDA-3, and it was superior to the natalizumab-to-other-DMT sequence across all secondary outcomes analyzed. In practical terms, this means the transplant strategy did not simply match inflammatory control. It appeared to produce a broader disease modification profile.
Age and baseline disability still shaped progression risk
Baseline age and Expanded Disability Status Scale score independently predicted PIRA across the full cohort. That finding fits the bedside reality of multiple sclerosis: even the most effective anti-inflammatory strategy has less room to preserve function once age-related immune changes and established neurologic injury are already in place.
The signal also helps frame the study’s main implication. If progression is partly driven by smoldering CNS inflammation and cumulative tissue injury, then earlier treatment should matter. Waiting until disability is more entrenched may reduce the ceiling of benefit, regardless of how aggressive the intervention is.
What this means for aggressive relapsing-remitting MS care
The results support a treatment model in which AHSCT is not viewed only as a rescue option for relapses, but as a strategy that may influence the long-term progression trajectory in aggressive relapsing-remitting MS. The comparison with natalizumab is clinically relevant because natalizumab remains a potent anti-inflammatory option, yet the study suggests that suppressing peripheral inflammation alone may not be enough to prevent later PIRA in every patient.
The biological explanation is plausible. Conditioning chemotherapy used in AHSCT may reach CNS compartments and disrupt inflammatory activity that survives outside the reach of many conventional therapies. If that is part of the mechanism, then the clinical advantage would be expected to appear most clearly after prolonged observation, exactly as seen here.
Still, this is a retrospective matched study from a single center, and the treatment decision was not randomized. The cohort was small, and 29 of 30 natalizumab-treated patients switched therapies during follow-up, which makes interpretation of longer-term comparisons more complex even when the analytic approach is careful. Those features do not erase the signal, but they do limit how far the findings can be generalized without caution.
The study leaves a concrete clinical question on the table: which aggressive relapsing-remitting MS patients are early enough in their disease course to gain the most from a CNS-active high-intensity strategy before PIRA becomes established? The available data suggest age and baseline disability are already working against patients by the time progression is visible. For neurologists, that makes timing and patient selection central to any discussion of transplantation versus continued escalation with disease-modifying therapy.